Clinicopathological analysis of Ret-rearranged lung carcinoma
| Project/Area Number |
25460446
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Human pathology
|
|---|
| Research Institution | Kansai Medical University (2015)
National Cancer Center Japan (2013-2014) |
|---|
Principal Investigator |
TSUTA Koji 関西医科大学, 医学部, 教授 (00392332)
|
|---|
| Project Period (FY) |
2013-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2014: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2013: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
|
|---|
| Keywords | 病理 / 肺癌 / RET / 遺伝子融合 / RET転座 / RET遺伝子 / 転座 |
|---|
| Outline of Final Research Achievements |
The aim of this study was to investigate the clinicopathological factors of RET-rearranged lung carcinoma. We detected 22 (1.2%) of RET-rearranged lung carcinoma. All of them were adenocarcinoma histology and they tended to be younger age occurrence and no smoking history. To develop the diagnostic test for small sample, we evaluated the utility of digital mRNA count method. To evaluate the desirable combination therapy in RET-rearranged lung carcinoma, we analyzed the expression pattern for βIII-tubulin, ribonucleotide reductase subunit M1, thymidylate synthase, and programmed cell death 1 receptor expression. There were no differences inβIII-tubulin, ribonucleotide reductase subunit M1, and thymidylate synthase expression between RET-rearranged lung carcinoma and wild type adenocarcinoma. Whereas, PD-L1 low expression was observed in RET-rearranged lung carcinoma compared to wild type adenocarcinoma.
|
Report
(4 results)
Research Products
(4 results)
